Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HOMOLOGY MEDICINES, INC.

(FIXX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
7.39(c) 7.35(c) 7.13(c) 7.26(c) 6.86(c) Last
618 454 601 548 505 767 539 927 1 427 378 Volume
+3.07% -0.54% -2.99% +1.82% -5.51% Change
More quotes
Financials (USD)
Sales 2021 27,7 M - -
Net income 2021 -103 M - -
Net cash position 2021 154 M - -
P/E ratio 2021 -3,51x
Yield 2021 -
Sales 2022 2,38 M - -
Net income 2022 -152 M - -
Net cash position 2022 4,70 M - -
P/E ratio 2022 -2,73x
Yield 2022 -
Capitalization 392 M 392 M -
EV / Sales 2021 8,59x
EV / Sales 2022 163x
Nbr of Employees 205
Free-Float 87,0%
More Financials
Company
Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The CompanyÔÇÖs lead product candidate, HMI-102 is a... 
More about the company
Ratings of Homology Medicines, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about HOMOLOGY MEDICINES, INC.
05/18HOMOLOGY MEDICINESá : Corporate and Pipeline Updates – May 2021
PU
05/18HOMOLOGY MEDICINESá : Canaccord Genuity Adjusts Homology Medicines' Price Target..
MT
05/13HOMOLOGY MEDICINESá : 05/13/2021 Homology Medicines Announces Presentations on i..
PU
05/13HOMOLOGY MEDICINESá : Announces Presentations on its Expanding Genetic Medicines..
AQ
05/12HOMOLOGY MEDICINESá : Corporate and Pipeline Updates – May 2021
PU
05/10HOMOLOGY MEDICINESá : Chardan Adjusts Price Target on Homology Medicines to $30 ..
MT
05/07HOMOLOGY MEDICINESá : Oppenheimer Adjusts Homology Medicines PT to $24 From $27,..
MT
05/06HOMOLOGY MEDICINES : Q1 Earnings Snapshot
AQ
05/06HOMOLOGY MEDICINESá : Management's Discussion and Analysis of Financial Conditio..
AQ
05/06HOMOLOGY MEDICINESá : Corporate Presentation - May 2021
PU
05/06HOMOLOGY MEDICINESá : 05/06/2021 Homology Medicines Reports First Quarter 2021 F..
PU
05/06Homology Medicines Reports First Quarter 2021 Financial Results and Recent Hi..
GL
05/03HOMOLOGY MEDICINESá : 05/03/2021 Homology Medicines Presents Data Demonstrating ..
PU
05/03Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Hu..
GL
04/28HOMOLOGY MEDICINESá : Corporate Presentation - April 2021
PU
More news
News in other languages on HOMOLOGY MEDICINES, INC.
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
04/07MÄRKTE USA/Kaum verändert - Fed-Protokoll ohne Überraschungen
04/07MÄRKTE USA/Börsen treten vor Fed-Protokoll auf der Stelle
04/07MÄRKTE USA/Zurückhaltung vor Fed-Protokoll
04/07MARKT USA/Wenig verändert vor Fed-Protokoll
More news
Analyst Recommendations on HOMOLOGY MEDICINES, INC.
More recommendations
Chart HOMOLOGY MEDICINES, INC.
Duration : Period :
Homology Medicines, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HOMOLOGY MEDICINES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 24,56 $
Last Close Price 6,86 $
Spread / Highest target 410%
Spread / Average Target 258%
Spread / Lowest Target 74,9%
EPS Revisions
Managers and Directors
NameTitle
Arthur O. Tzianabos President, Chief Executive Officer & Director
W. Bradford Smith Chief Financial Officer, Secretary & Treasurer
Kush M. Parmar Chairman
Albert Seymour Chief Scientific Officer
Gabriel M. Cohn Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HOMOLOGY MEDICINES, INC.-39.24%392
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628